Unity Biotechnology Inc (NAS:UBX)
$ 1.21 -0.05 (-3.97%) Market Cap: 20.39 Mil Enterprise Value: 8.73 Mil PE Ratio: 0 PB Ratio: 1.44 GF Score: 36/100

UNITY Biotechnology Inc To Discuss The UBX1325 Clinical Data Call Transcript

Jul 27, 2021 / 03:00PM GMT
Release Date Price: $38.2
Operator

Good day, and thank you for standing by. Welcome to the Unity Biotechnology KOL Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Lynne Sullivan, Chief Financial Officer. Please go ahead.

Lynne Marie Sullivan
Unity Biotechnology, Inc. - CFO & Head of Corporate Development

Good morning. Thank you for joining Unity Biotechnology's conference call this morning to discuss the Phase I results from our UBX1325 program. With me on today's call is Robert Bhisitkul, Professor of Ophthalmology and Director of the Retina Fellowship at University of California San Francisco, a renowned retinal specialist; Anirvan Ghosh, the CEO of Unity Biotechnology; Jamie Dananberg, the Chief Medical Officer of Unity Biotechnology; and myself, Lynne Sullivan, the Chief Financial Officer.

Before turning the call over to Anirvan, I'd like to remind you that during today's call, we'll be making some forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot